We are live on ! Find out more
ANTH

Anthera Pharmaceuticals, Inc.
ANTH

Delisted

ANTH was delisted on the 27th of June, 2018.

33 hedge funds and large institutions have $27.4M invested in Anthera Pharmaceuticals, Inc. in 2013 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 5

14% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 7

3% more funds holding

Funds holding: 3233 (+1)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

23% less capital invested

Capital invested by funds: $35.7M → $27.4M (-$8.29M)

Holders
33
Holders Change
+1
Holders Change %
+3.13%
% of All Funds
0.96%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
8
Increased
8
Reduced
5
Closed
7
Calls
$94K
Puts
Net Calls
+$94K
Net Calls Change
+$94K

ANTH Hedge Fund Activity: Q4 2013 in Review

33 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Anthera Pharmaceuticals, Inc. (ANTH) for Q4 2013, worth a combined $27.4M — down 23% from $35.7M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new ANTH positions and 7 closed out — a net gain of 1 holder — while 8 added to existing stakes and 5 trimmed.

The largest buyer was Moore Capital Management, opening a new position worth an estimated $724K. The largest seller was Bailard, exiting entirely with an estimated $708K sold.

  • 33 institutional investors held Anthera Pharmaceuticals, Inc. (ANTH) as of Q4 2013, up from 32 in Q3 2013.
  • Funds reported $27.4M of Anthera Pharmaceuticals, Inc. stock for Q4 2013, down 23% quarter-over-quarter.
  • 8 funds opened new Anthera Pharmaceuticals, Inc. positions in Q4 2013 and 7 closed out, a net change of +1 holder.
  • The largest Anthera Pharmaceuticals, Inc. buyer in Q4 2013 was Moore Capital Management, an estimated $724K added.
  • The largest Anthera Pharmaceuticals, Inc. seller in Q4 2013 was Bailard, an estimated $708K sold.

Based on aggregated 13F filings for Q4 2013.